Exicure
Biotechnology, 2430 N Halsted St, Chicago, Illinois, 60614, United States, 11-50 Employees
Phone Number: 84********
Who is EXICURE
Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Our t...
Read More
-
Headquarters: 2430 N Halsted St, Chicago, Illinois, 60614, United States
-
Date Founded: 2011
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 531210 |
Show More
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Exicure
Answer: Exicure's headquarters are located at 2430 N Halsted St, Chicago, Illinois, 60614, United States
Answer: Exicure's phone number is 84********
Answer: Exicure's official website is https://exicuretx.com
Answer: Exicure's revenue is $25 Million to $50 Million
Answer: Exicure's SIC: 2834
Answer: Exicure's NAICS: 531210
Answer: Exicure has 11-50 employees
Answer: Exicure is in Biotechnology
Answer: Exicure contact info: Phone number: 84******** Website: https://exicuretx.com
Answer: Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Our team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, IL, Exicure conducts its discovery and development efforts in-house with a dedicated 30,000 sq. ft. facility, including rapid and automated high throughput nucleic acid synthesis and screening. Our platform for therapeutic nucleic acids demonstrates high potency, broad uptake, and prolonged efficacy in both in vitro and in vivo neurological models. The basis of our discovery approach harnesses our expertise in oligonucleotide chemistry to validated targets where we can screen thousands of oligonucleotides efficiently and validate top candidates in the appropriate cell and live animal models. Exicure's lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A (Nav1.7). Exicure has also identified several promising candidates across a series of CNS conditions with high unmet need including Huntington disease, Angelman syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month